Medtronic plc Q4 2026 Earnings Recap

Shares rallied 11.1% as investors responded positively to strong organic revenue growth and robust execution in high-growth platforms, particularly in Cardiac Ablation Solutions (CAS) and advances in surgical robotics.

Key Takeaways

• Q4 revenue reached $9.8 billion, up 6.6% organically and 9.9% reported, marking the strongest top-line performance in a decade.
• Adjusted EPS was $1.55 in Q4 and $5.53 for fiscal year 2026, reflecting disciplined operational execution.
• CAS grew 78% globally, driven by PFA’s 145% growth and an expanded U.S. installed base up 40% sequentially.
• Symplicity, the minimally invasive hypertension treatment, is annualizing at $100 million with growing physician adoption and procedure volumes.
• Hugo surgical robotics procedures grew 2 to 3 times faster than the market, with recent U.S. rollout and promising early clinical feedback.